Global Pulmonary Drugs Market Research Report 2012-2024

Table of Contents

1 Market Overview

• 1.1 Objectives of Research
  • 1.1.1 Definition
  • 1.1.2 Specifications
• 1.2 Market Segment
  • 1.2.1 by Type
    • 1.2.1.1 Inhaled Corticosteroids (ICS)
    • 1.2.1.2 Long-Acting Beta2-Agonists (LABA)
    • 1.2.1.3 Antihistamine
    • 1.2.1.4 Vasodilators
    • 1.2.1.5 Short-Acting Beta2-Agonists (SABA)
    • 1.2.1.6 Anticholinergics
    • 1.2.1.7 Combination Drugs
    • 1.2.1.8 MAbs
    • 1.2.1.9 Enzymes
    • 1.2.1.10 Antibiotics & Antileukotrienes
  • 1.2.2 by Application
    • 1.2.2.1 Asthma & COPD
    • 1.2.2.2 Allergic Rhinitis
    • 1.2.2.3 Pulmonary Arterial Hypertension
    • 1.2.2.4 Cystic Fibrosis
  • 1.2.3 by Regions

2 Industry Chain

• 2.1 Industry Chain Structure
• 2.2 Upstream
• 2.3 Market
  • 2.3.1 SWOT
  • 2.3.2 Dynamics

3 Environmental Analysis

• 3.1 Policy
• 3.2 Economic
• 3.3 Technology
• 3.4 Market Entry

4 Market Segmentation by Type

• 4.1 Market Size
  • 4.1.1 Inhaled Corticosteroids (ICS) Market, 2013-2018
  • 4.1.2 Long-Acting Beta2-Agonists (LABA) Market, 2013-2018
  • 4.1.3 Antihistamine Market, 2013-2018
  • 4.1.4 Vasodilators Market, 2013-2018
  • 4.1.5 Short-Acting Beta2-Agonists (SABA) Market, 2013-2018
  • 4.1.6 Anticholinergics Market, 2013-2018
  • 4.1.7 Combination Drugs Market, 2013-2018
  • 4.1.8 MAbs Market, 2013-2018
  • 4.1.9 Enzymes Market, 2013-2018
  • 4.1.10 Antibiotics & Antileukotrienes Market, 2013-2018
• 4.2 Market Forecast
  • 4.2.1 Inhaled Corticosteroids (ICS) Market Forecast, 2019-2024
  • 4.2.2 Long-Acting Beta2-Agonists (LABA) Market Forecast, 2019-2024
  • 4.2.3 Antihistamine Market Forecast, 2019-2024
  • 4.2.4 Vasodilators Market Forecast, 2019-2024
  • 4.2.5 Short-Acting Beta2-Agonists (SABA) Market Forecast, 2019-2024
  • 4.2.6 Anticholinergics Market Forecast, 2019-2024
  • 4.2.7 Combination Drugs Market Forecast, 2019-2024
  • 4.2.8 MAbs Market Forecast, 2019-2024
  • 4.2.9 Enzymes Market Forecast, 2019-2024
  • 4.2.10 Antibiotics & Antileukotrienes Market Forecast, 2019-2024

5 Market Segmentation by Application

• 5.1 Market Size
  • 5.1.1 Asthma & COPD Market, 2013-2018
  • 5.1.2 Allergic Rhinitis Market, 2013-2018
  • 5.1.3 Pulmonary Arterial Hypertension Market, 2013-2018
  • 5.1.4 Cystic Fibrosis Market, 2013-2018
• 5.2 Market Forecast
  • 5.2.1 Asthma & COPD Market Forecast, 2019-2024
  • 5.2.2 Allergic Rhinitis Market Forecast, 2019-2024
  • 5.2.3 Pulmonary Arterial Hypertension Market Forecast, 2019-2024
  • 5.2.4 Cystic Fibrosis Market Forecast, 2019-2024

6 Market Segmentation by Region

• 6.1 Market Size
  • 6.1.1 Asia-Pacific
    • 6.1.1.1 Asia-Pacific Market, 2012-2018
    • 6.1.1.2 Asia-Pacific Market by Type
    • 6.1.1.3 Asia-Pacific Market by Application
  • 6.1.2 North America
    • 6.1.2.1 North America Market, 2012-2018
    • 6.1.2.2 North America Market by Type
    • 6.1.2.3 North America Market by Application
  • 6.1.3 Europe
    • 6.1.3.1 Europe Market, 2012-2018
    • 6.1.3.2 Europe Market by Type
    • 6.1.3.3 Europe Market by Application
  • 6.1.4 South America
    • 6.1.4.1 South America Market, 2012-2018
    • 6.1.4.2 South America Market by Type
    • 6.1.4.3 South America Market by Application
  • 6.1.5 Middle East & Africa
    • 6.1.5.1 Middle East & Africa Market, 2012-2018
    • 6.1.5.2 Middle East & Africa Market by Type
    • 6.1.5.3 Middle East & Africa Market by Application
• 6.2 Market Forecast
  • 6.2.1 Asia-Pacific Market Forecast, 2019-2024
  • 6.2.2 North America Market Forecast, 2019-2024
  • 6.2.3 Europe Market Forecast, 2019-2024
  • 6.2.4 South America Market Forecast, 2019-2024
  • 6.2.5 Middle East & Africa Market Forecast, 2019-2024

7 Market Competitive

• 7.1 Global Market by Vendors
• 7.2 Market Concentration
• 7.3 Price & Factors
• 7.4 Marketing Channel

8 Major Vendors

• 8.1 AstraZeneca plc
• 8.2 Bayer AG
• 8.3 Teva Pharmaceutical Industries Ltd
• 8.4 Actelion Pharmaceuticals, Inc.
• 8.5 Boehringer Ingelheim GmbH
• 8.6 F. Hoffmann-La Roche Ltd.
• 8.7 Merck & Co., Inc.
• 8.8 Novartis AG
• 8.9 GlaxoSmithKline plc
• 8.10 Sunovion Pharmaceuticals

9 Conclusion